The Race to Modernize Viral Vector Production

Automation and consolidation are reshaping viral vector manufacturing, forcing producers to modernize early to stay competitive and reliable

5 Feb 2026

The viral vector manufacturing industry is entering a more decisive phase as gene therapy pipelines expand across North America. Once a niche segment of biopharmaceutical production, the field has become a strategic arena in which speed, scale and reliability increasingly determine which companies secure long-term partnerships and commercial relevance.

Rising demand has exposed the limits of traditional production models, which have often struggled to deliver consistent supply at the pace required for advancing clinical programs. Bottlenecks in manufacturing have delayed trials and, in some cases, slowed patient access. In response, manufacturers are accelerating investments in automation, digital manufacturing platforms and process standardization, seeking to make production more predictable and scalable.

Digital biomanufacturing approaches are gaining traction as a way to improve consistency, shorten turnaround times and support larger output volumes. Frost & Sullivan has identified digital manufacturing as a central driver of speed, scale and resilience in gene therapy supply chains, reflecting a broader view that these tools are becoming foundational as the sector matures rather than optional enhancements.

Competition in the market is shifting alongside these changes. Sponsors are increasingly prioritizing partners that can demonstrate dependable supply at commercial scale over extended time horizons. Lonza has continued to expand and modernize its viral vector manufacturing capabilities, while Thermo Fisher Scientific offers integrated production platforms intended to improve throughput and consistency across larger batches, according to company statements.

Consolidation and strategic partnerships are also reshaping the landscape. Established manufacturers, including Catalent, have moved toward more integrated, end-to-end service models designed to simplify the path from early development through commercialization. Such approaches appeal to smaller biotechnology firms seeking to reduce complexity as their programs advance.

Analysts describe these developments as part of a broader transition toward industrial-scale gene therapy manufacturing. Digital systems are increasingly seen as essential to meeting regulatory expectations and maintaining tighter control over quality as volumes grow.

Challenges persist, particularly around regulatory oversight and access for smaller developers with limited capital. Still, the direction of travel appears set. Viral vector production is being rebuilt on a more modern foundation, and companies that invest early in digital capabilities and scalable infrastructure are likely to influence how gene therapies are manufactured and delivered in the years ahead.